scout
Opinion|Videos|August 29, 2024

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Episodes in this series

Video content above is prompted by the following:

  • Briefly share perspective/insights on emerging novel agents in R/R CLL: 2nd gen BCL2 inhibitors 

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME